GASTRIC CANCER

This study tests whether adding a new experimental drug (HLX22) to the standard two-drug treatment can help people with advanced HER2-positive stomach or gastroesophageal cancer live longer without their cancer growing. About 550 adults who have not had prior treatment for their …

This study tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers (like breast, stomach, lung, or ovarian cancer) that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how long that effect last…

This early-stage trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with untreated stomach or esophageal cancer that cannot be removed by surgery. The study includes two groups: one for HER2-negative cancer and one for HER2-positive …

This study tests a new drug, AZD0901, against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has not responded to prior therapy. The trial includes 572 adults whose tumors have a specific marker called CLDN18.2. The main goals are to…

This study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy and radiation can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standa…

This study tests a combination of three drugs (RC48, sintilimab, and SOX chemotherapy) in 30 people with advanced stomach cancer that cannot be removed by surgery. The goal is to shrink the tumor enough so that surgery becomes possible. Participants receive 4 to 6 cycles of treat…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another c…

This study tests whether adding an immunotherapy drug (anti-PD-1) and an immune booster (thymalfasin) to standard chemotherapy (SOX) before surgery can help shrink stage III stomach or gastroesophageal junction cancer. About 30 adults aged 18-75 with HER2-negative cancer will rec…

This study tests a combination of immunotherapy drugs (sintilimab, IBI310, lenvatinib) in people with non-spreading stomach or colon cancers that have a specific genetic feature (MSI-H/dMMR). The goal is to see if these drugs can make the cancer disappear or shrink enough so that…

This early-phase study tests a new treatment called Anti-CEA CAR-T for people with advanced solid tumors (like colorectal or stomach cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target a protein called CEA fou…

This early-phase study tests a new drug called AZD4360 in adults with advanced stomach, bile duct, or pancreatic cancers that have not responded to prior treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 117 participa…

This study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer progressed after first-line platinum…

This study is for people with stomach cancer that has spread to the lining of the belly and causes fluid buildup (ascites). It tests a combination of three drugs: lenvatinib, nivolumab, and chemotherapy. The goal is to see if this combination can help control the cancer and impro…

This early-phase trial tests a new drug called TH9619 in 43 adults with advanced solid tumors (colorectal, head and neck, lung, or stomach cancer) that have not responded to prior treatment. The main goal is to find a safe dose and check for side effects. Researchers will also wa…

This early-stage study tests a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors (such as lung, stomach, colon, rectal, esophageal, or pancreatic cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This study tests a new treatment for people with certain advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12V. The treatment involves taking a patient's own white blood cells, modifying them in a lab to better recognize…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with other treatments, in people with advanced HER2-positive stomach cancer. About 450 adults with cancer that has spread will take part. The goal is to see if the drug shrinks tumors and is safe, but it is n…

This early-phase study tests a new drug called BL-M07D1 in adults with advanced HER2-positive solid tumors (including breast, lung, stomach, and ovarian cancers) that have not responded to at least two prior treatments. The main goals are to check the drug's safety, find the best…

This study tests whether using a reinforcement patch on the stapler during stomach cancer surgery can reduce complications like leaks. About 382 adults with gastric cancer will be randomly assigned to get either the patch or a standard stapler. The main goal is to see if the patc…

This study tests a software tool called myDIET that helps manage nutrition for people with stomach or esophageal junction cancer who are scheduled for surgery. The goal is to see if using the app helps patients start their follow-up chemotherapy sooner after surgery. About 60 adu…

This study tests a combination of two or three drugs (cabozantinib, durvalumab, and possibly tremelimumab) in people with advanced stomach, esophageal, liver, or colorectal cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the treatment can …

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific marker (CLDN18.2). The goal is to see if it is safe and shrinks tumors. About 224 adults with stomach, bile duct, or pancreatic cancer will take…

This study tests new combinations of drugs for people with advanced stomach cancer that cannot be removed by surgery or has spread. About 163 adults will receive these treatments to see if they can shrink tumors or slow the cancer's growth. The goal is to find better ways to cont…

This early-phase study tests an experimental drug called MRG007 in people with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also seei…

This study tests whether adding a gut microbiome supplement (EXL01) to standard immunotherapy (nivolumab) and chemotherapy (FOLFOX) helps shrink tumors in people with advanced stomach cancer. About 120 participants will be randomly assigned to receive the supplement or not. The g…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein called CEACAM5. The drug is designed to deliver a chemotherapy-like payload directly to cancer cells. The trial aims to see i…

This study tests whether adding a probiotic (Saccharomyces boulardii) to a standard 4-drug antibiotic regimen helps clear H. pylori infection in people whose past treatment failed. About 1,248 adults will be randomly assigned to get either the probiotic plus antibiotics or antibi…

This early-stage trial tests an investigational drug called JR8603 in about 94 adults with advanced solid tumors (including stomach, junction, and colorectal cancers) whose prior treatments have stopped working. The main goals are to check safety, find the best dose, and see if t…

This study looks at whether a diet low in leucine (an amino acid) is safe and can make chemotherapy and immunotherapy work better for people with stomach cancer. About 108 adults with locally advanced stomach cancer will follow this diet alongside their standard treatment. The go…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-stage study tests a new drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 330 partici…

This study compares standard chemotherapy alone versus standard chemotherapy plus a special procedure called PIPAC (where chemotherapy is sprayed directly into the abdomen) for people with stomach cancer that has spread to the lining of the abdomen. About 106 adults aged 18-75 wi…

This early-stage study tests a new treatment called IVX037, a virus injected directly into tumors, for people with advanced colorectal, stomach, or ovarian cancers that have stopped responding to standard treatments. The study has two parts: first, testing IVX037 alone, then comb…

This program provides access to an experimental drug called AVM0703 for people with various solid tumors or blood cancers who have not responded to other treatments. It is available in the US upon a doctor's request. So far, 37 patients have received the drug, and side effects ha…

This early-phase study tests a new drug called BL-M17D1 in about 20 people with advanced HER2-positive or low-HER2 cancers of the digestive tract (esophagus, stomach, pancreas, colon) and other solid tumors. The main goals are to check safety, find the best dose, and see if the d…

This phase 3 trial tests whether a newer targeted drug (Enhertu) combined with chemotherapy and an immunotherapy (pembrolizumab) works better than the current standard treatment for advanced HER2-positive stomach or gastroesophageal junction cancer. About 726 adults who have not …

This study tests whether giving heated chemotherapy directly into the abdomen during stomach cancer surgery can help patients live longer and lower the chance of cancer coming back. About 616 adults with advanced stomach cancer will be split into two groups: one gets standard sur…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This study tests a two-step treatment for people with advanced liver cancer or stomach cancer that has spread to the liver. First, a drug called tirapazamine is injected directly into the liver's blood vessels to block and kill tumor cells. Then, patients receive nivolumab, an im…

This study tests whether combining the immunotherapy drug adebrelimab with other targeted drugs and chemotherapy can help shrink tumors in people with stomach or gastroesophageal junction cancer. About 200 adults who have not had prior treatment for their cancer will receive one …

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This early-phase trial tests a new drug called MDX2001 in about 285 adults with advanced solid tumors (cancers that have spread). The main goals are to check the drug's safety and find the right dose. Researchers will also see if it shrinks tumors. This is not a cure, but it may …

This early-phase trial tests a combination of two targeted drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have stopped responding to standard treatments. The main goal is to find the s…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or relapsed acute myeloid leukemia (AML). The main goals are to check safety and find the best dose. About 260 adults will take part acr…

This study tests three experimental treatments for people with advanced esophageal, stomach, or colorectal cancers that have spread. The goal is to see if these drug combinations can shrink tumors and how safe they are. About 376 adults aged 18 to 75 will participate. The treatme…

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…

This study tests a new drug, sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly another drug (rilvegostomig) for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specific marker (CLDN18.2) and is HER2-negative. Abou…

This early-stage trial tests a new radioactive drug, [225Ac]-FPI-2068, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see how the drug spreads in the body. About 70 people with cancers like lung, colon, …

This study compares two types of stomach cancer surgery to see which one causes less acid reflux and better quality of life. About 60 people with stomach cancer will be randomly assigned to one of the two operations. The goal is to find the best surgical approach to control the d…

This early-stage study tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose. About 450 adults with cancers like lung, …

This study tests a new combination of drugs—neratinib, trastuzumab, pembrolizumab, and chemotherapy—in people with HER2-positive stomach or esophageal cancer. The goal is to see how well the treatment shrinks tumors and controls the disease. About 36 adults will take part, and th…

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This study tests an experimental drug called AZD5863 in adults with advanced stomach, esophageal, or pancreatic cancers that have spread. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to check safety and see if the drug can shrink tu…

This early-phase study tests a new drug, SON-DP, in about 96 adults with advanced solid tumors, including liver and gastric cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants must have measurab…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This early-phase study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic markers (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This study tests whether two drugs, avutometinib and defactinib, can slow or shrink tumors in people with a specific type of advanced stomach cancer called diffuse gastric cancer. About 27 participants who have already tried at least one standard treatment will receive the drug c…

This early-stage study tests an experimental drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug works by boosting the immune system to fight tumors. The main goals are to check safety and find the right dose, with a later …

This study tests a personalized cancer vaccine made from patients' own tumor cells. The goal is to train the immune system to fight metastatic cancers like melanoma, breast, lung, and colorectal cancer. Participants receive eight injections over 16 weeks. The study is for adults …

This study is testing a new drug called Dato-DXd, either alone or with other cancer drugs, in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gastric, prost…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to activate the immune system, followed by an infusion…

This study is for people with stomach cancer that has spread to a few other places in the body. It tests whether adding surgery to remove the main tumor and some of the spread, along with other local treatments, to a mix of immunotherapy and chemotherapy helps people live longer …

This study is testing an experimental drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their…

This study tests a new drug called GAIA-102, given alone or with another drug (pembrolizumab), for people with advanced stomach or pancreatic cancer that has spread and causes fluid buildup in the belly (malignant ascites). The first part checks safety and the best dose, and the …

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests if taking oral sorbitol (a common sugar alcohol) can make standard chemotherapy and immunotherapy work better for people with locally advanced stomach cancer. About 80 adults will receive either sorbitol or a placebo alongside their cancer treatment. The goal is …

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This early-stage trial tests a new drug called IKS014 in people with advanced HER2-positive breast, stomach, or gastroesophageal cancers that have not responded to other treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells that have high leve…

This study tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has not responded to initial treatment. About 60 participants will receive either a two-drug or three-drug combination to see if adding a third drug improves outcomes…

This study is testing a new treatment that uses a radioactive substance to target and destroy cancer cells in people with advanced solid tumors (like pancreatic, stomach, or ovarian cancer) that have not responded to standard treatments. The therapy works by attaching to a protei…

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with other rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if their tumors shrink or stop growing for at least 24 weeks. The goal is to fi…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack canc…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study looks at different second-line drug combinations for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. Researchers want to see which combination works best and is safest. About 250 adults aged 18 to 80 who are o…

This study tests a combination of two drugs (carilizumab and albumin paclitaxel) as a second treatment for people with advanced stomach cancer. It includes 40 adults who have already tried one prior treatment, with or without immunotherapy. The goal is to see if the combo can slo…

This study tests whether taking glutamine by mouth can help people with stomach cancer recover muscle mass and nutrition after having their stomach removed. About 120 adults who had stomach cancer surgery will take glutamine supplements, and researchers will measure changes in mu…

This phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal…

This study is testing a simple, non-invasive method to detect early signs of Barrett's esophagus, esophageal cancer, and stomach cancer. Participants swallow a capsule attached to a string that collects cells from the esophagus and stomach. Researchers then analyze the DNA in tho…

This study tests a new type of PET scan that looks for a protein called CLDN18.2 on cancer cells. It includes 56 adults with stomach, pancreatic, bile duct, or esophageal cancer, plus healthy volunteers. The goal is to see if this scan can accurately find tumors and help doctors …

This study tests a new fluorescent dye that targets cancer cells to help doctors see which lymph nodes contain cancer during stomach cancer surgery. About 47 people with early stomach cancer will have their removed lymph nodes examined with this probe. The goal is to avoid removi…

This study tests a special dye and imaging system that makes cancer cells glow, helping surgeons see and remove tumors more completely during surgery for colorectal, pancreatic, esophageal, and gastric cancers. About 66 adults scheduled for surgery will receive the dye beforehand…

This study tests a new imaging agent called [18F]FPyQCP for PET scans to better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the agent and undergo PET/CT imaging. The goal is to see if it i…

This study aims to see if certain chemicals in a person's breath and blood can help detect early-stage gastro-esophageal cancer. Researchers will compare samples from people with cancer, those with Barrett's esophagus (a pre-cancer condition), and healthy volunteers. Participants…

This study is testing a new blood test that looks for tiny particles called exosomal microRNAs to find leftover stomach cancer cells after surgery. The goal is to catch a recurrence earlier than standard scans. The study will involve 500 people who had their stomach cancer remove…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study tests whether a dye called CYTALUX™, given before surgery, can help surgeons see cancer tissue in real time using a special camera. It includes 15 adults with stomach, esophagus, or appendix cancer who are already scheduled for surgery. The goal is to see if this techn…

This study aims to prevent gastric cancer in Aboriginal people in remote Taiwan by testing and treating a common stomach infection called H. pylori. The study will involve up to 50,000 adults aged 20-60. Researchers will measure how well the treatment works and whether it reduces…

This study compares a new type of stomach bypass surgery (partial stomach-partitioning gastrojejunostomy) to the standard surgery for people with advanced stomach cancer that blocks food from leaving the stomach. The goal is to see which surgery better relieves the blockage, redu…

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients (BMI 28 or higher) undergoing sedated gastrointestinal endoscopy. The device combines oxygen support, airway management, and monitoring to reduce the risk of hypoxia (low oxygen le…

This study tests whether a special airway device (COMBO Endoscopy Oropharyngeal Airway) combined with high-flow oxygen can prevent low oxygen levels in severely obese patients during sedated endoscopy. About 410 adults with a BMI of 35 or higher will be randomly assigned to recei…

This study tests whether adding personalized integrative care—like naturopathic support, a Mediterranean diet, and physical activity—before and after surgery can improve quality of life and reduce complications for people with lung, stomach, or esophageal cancer. About 20 adults …

This study is testing a structured rehabilitation program for 100 people in southern Sweden who have esophageal or stomach cancer and are scheduled for surgery. The goal is to see if the program can improve quality of life and reduce cancer-related symptoms. Participants will be …

This study tests whether a smartphone-based rehab program can reduce complications and improve recovery in people with stomach cancer who receive chemotherapy before surgery. About 186 participants will follow the program from before surgery until four weeks after leaving the hos…

This study tests whether a dye called indocyanine green, which glows under a special camera, helps surgeons see and remove more lymph nodes during stomach cancer surgery. About 360 adults with advanced stomach cancer will take part. The goal is to see if the dye changes how the s…

This study looks back at 1,200 patients who had a breathing tube placed during general anesthesia for non-throat surgeries. Researchers want to find out how often throat injuries like hoarseness or sore throat happen, what factors increase the risk, and how patients recover. The …

This study is for adults who carry a specific change in the CTNNA1 gene or are close relatives of someone who does. The goal is to find out how much this gene change raises the risk for stomach cancer, breast cancer, and other cancers. Researchers will collect family health histo…

This study looks at whether adding a geriatrician to the care team can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online fitness questionnaire is easy to use and if geriatric c…

This study is building a registry of 3,200 people with early stomach changes that can lead to cancer, such as gastric atrophy or intestinal metaplasia. Researchers will also include healthy people and those with stomach cancer for comparison. The goal is to learn which risk facto…

This study collects tissue, blood, urine, and stool samples from 5,000 people undergoing colonoscopy or endoscopy, including those with cancer, polyps, or inflammatory bowel disease, as well as healthy volunteers. The goal is to find new biomarkers that could lead to better scree…

This study aims to understand why some cancers come back after surgery by detecting tumor cells and DNA in blood, urine, and bone marrow. Researchers will collect samples from 620 adults with various solid cancers (like lung, colon, or pancreatic cancer) and track their health ov…

This study is developing an AI model to predict the risk of serious bleeding after stomach cancer surgery, helping doctors decide if a second operation is needed. It will involve 7,000 adult patients who have had their stomach removed due to cancer. The AI will analyze routine me…

This study looks at whether the bacteria in your gut can help predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. About 300 adults with metastatic or locally advanced stomach cancer who haven't had chemo or immunotherapy before will…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, liver, stomach) who are starting immunotherapy. Researchers will track ctDNA levels in the blood to see if changes can predict early whether the treatment is working. They will also look at other m…

This study is building a registry of people with gastric cancer, a family history of it, or a CDH1 gene mutation. Participants fill out online questionnaires and provide saliva, blood, or tissue samples. The goal is to learn what causes the disease and whether genetic information…

This study aims to describe the features of gastric cancer in 1,000 patients in Algeria, including their demographics, risk factors, symptoms, and how the disease is diagnosed and treated. Researchers will collect data from medical records and follow patients over time to underst…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. About 600 participants will give blood samples before and during treatment. The goal is to see if …

This study looks at muscle wasting, weight loss, and tiredness in people with stomach, pancreas, or bowel cancer who are having surgery. Researchers will track changes in body composition, physical activity, and quality of life over a year. The goal is to better understand cachex…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study is looking for blood markers that can show early changes in the stomach lining that might lead to cancer. Researchers will follow 192 adults who are already getting stomach function tests to see if certain molecules in the blood can predict who is at higher risk. The g…

This study is testing whether a personalized blood test that looks for tumor DNA can detect the return of stomach cancer earlier than standard imaging. Researchers will follow 110 patients who had chemotherapy and surgery for stage II-III stomach cancer. The goal is to see how ac…

This study looks at whether giving heated chemotherapy directly into the abdomen during keyhole surgery can increase a protein called PD-L1 in stomach cancer that has spread to the lining of the belly. PD-L1 helps doctors decide if immunotherapy might work. The trial involves 21 …

This study looks at tissue samples from 30 people with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic features of the original tumor and the brain tumor to see if they differ. The goal is to understand how the cancer changes when it spreads…

This study looks at a specific gene change (called hMLH1 hypermethylation) in stomach cancer to understand why it happens and how it affects treatment. Researchers will study 245 patients who had stomach cancer surgery to find links between lifestyle, diet, and this gene change. …

This study collects blood, urine, and bone marrow samples from 320 people with solid cancers (like lung, colon, or pancreatic cancer) and from those undergoing lung cancer screening. The goal is to detect tiny bits of tumor cells and DNA in these fluids to learn how cancer spread…

This study looks at genetic information from stomach cancer tumors to predict how well a patient will respond to chemotherapy after surgery. Researchers will use machine learning to analyze these genetic patterns and create a model that helps doctors decide who is most likely to …

This study is testing whether a new machine that combines radiation therapy with real-time MRI imaging is safe and practical for treating several types of cancer, including stomach and breast cancer. About 70 adults will receive this treatment along with chemotherapy. The goal is…

This study uses a 20-25 minute survey to find out which features of diagnostic tests for gastro-esophageal cancer matter most to patients and the general public. Researchers aim to understand preferences and regional differences to improve screening decisions. Over 2,200 adults a…

This study follows 600 people at higher risk for stomach cancer to learn how precancerous changes in the stomach lining progress or reverse over time. Participants are adults aged 35-84 having an endoscopy for reasons like stomach pain or a family history of stomach cancer. Resea…

This study follows 400 people with gastrointestinal stromal tumors (GISTs) to collect tumor tissue and blood samples for research. Participants are monitored every 6-12 months for up to 10 years before surgery, and then for 5 years after. The goal is to better understand the dise…